International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Frontiers in Genome Editing, published by FRONTIERS MEDIA SA, stands at the forefront of genomic research, specializing in the rapidly evolving realm of gene editing technologies. With an enthusiastic commitment to open access since 2020, this journal facilitates unrestricted distribution of cutting-edge research, making significant advancements in biotechnology and genetics accessible to a global audience. Located in Lausanne, Switzerland, Frontiers in Genome Editing publishes high-quality, peer-reviewed articles that contribute to the understanding and application of genome editing tools, such as CRISPR and TALEN, in various biological fields. Notably, as of 2023, the journal holds a prestigious Q1 ranking in Biotechnology and a Q2 ranking in Genetics, underscoring its importance and influence within these disciplines. With robust Scopus rankings, including a notable percentile placement, Frontiers in Genome Editing is an invaluable resource for researchers, professionals, and students dedicated to the promising future of genomic innovation.

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

EXPERIMENTAL ANIMALS is a leading journal that serves the vibrant fields of Animal Science, Veterinary Medicine, and Biochemistry, Genetics, and Molecular Biology, published by the prestigious INT PRESS EDITING CENTRE INC in Japan. Boasting an impressive track record since its inception in 1974, the journal has positioned itself as a crucial platform for researchers aiming to disseminate innovative findings in experimental animal research. With a commendable impact factor and categorized in the Q2 and Q3 quartiles by Scopus in various relevant fields for 2023, EXPERIMENTAL ANIMALS exemplifies excellence in its contributions to science. The journal offers a comprehensive range of articles spanning from animal welfare and experimental methodologies to genetic studies, ensuring a multidisciplinary approach that appeals to a diverse audience of researchers, professionals, and students. Access to its wealth of knowledge fosters significant advancements in research and practice, underlining the journal's commitment to enhancing understanding of animal models in scientific inquiry.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

Science China-Life Sciences, published by SCIENCE PRESS, is a premier academic journal that stands at the forefront of innovative research and discoveries in the fields of life sciences, spanning crucial areas such as agricultural and biological sciences, biochemistry, genetics, molecular biology, and environmental science. With an impressive Q1 ranking in its respective categories—ranked #5 in Agricultural and Biological Sciences, #7 in Environmental Science, and #17 in Biochemistry, Genetics and Molecular Biology—this journal is recognized for its rigorous peer-review process and significant impact within the scientific community, as reflected in its high percentiles (97th and 92nd). Maintained as an Open Access publication, it ensures broad dissemination and accessibility of research findings, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Given its position in the research landscape and its commitment to high-quality scholarship, Science China-Life Sciences plays a vital role in advancing life sciences research, supporting scientists in addressing global challenges through innovative biological solutions.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

Cell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.

Molecular Therapy Methods & Clinical Development, published by CELL PRESS, is a premier Open Access journal dedicated to advancing the field of gene and cell therapy through innovative methodologies and clinical developments. Since its inception in 2014, the journal has garnered significant attention within the research community, achieving impressive Q1 quartile rankings in Genetics, Molecular Biology, and Molecular Medicine as of 2023. With a commendable Scopus ranking that positions it within the top echelons of its categories, this journal serves as an essential platform for researchers, professionals, and students alike, providing access to cutting-edge research that drives the future of therapeutic approaches. With its commitment to Open Access, readers worldwide can easily access high-quality and impactful content that fosters collaboration and knowledge-sharing in this rapidly evolving domain. The journal’s scope encompasses crucial advancements in therapeutic methodologies, ensuring that it remains at the forefront of scientific discourse and innovation.